BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36627051)

  • 1. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?
    Wang M; Su J; Lu J; Yang Z; Wang J; Zhong Y; Zeng T; Shen K; Lin S
    Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102078. PubMed ID: 36627051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.
    Gao M; Jiang T; Li P; Zhang J; Xu K; Ren T
    Pharmacol Res; 2022 Aug; 182():106330. PubMed ID: 35781058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.
    Zeng T; Fang X; Lu J; Zhong Y; Lin X; Lin Z; Wang N; Jiang J; Lin S
    Int J Colorectal Dis; 2022 Jan; 37(1):251-258. PubMed ID: 34716473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis.
    Li Z; Guo S; Xue H; Li L; Guo Y; Duan S; Zhu H
    Front Pharmacol; 2023; 14():1183514. PubMed ID: 37426807
    [No Abstract]   [Full Text] [Related]  

  • 5. A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).
    Chitkara A; Bakhtiar M; Sahin IH; Hsu D; Zhang J; Anamika F; Mahnoor M; Ahmed R; Gholami S; Saeed A
    Curr Oncol; 2023 Sep; 30(9):8266-8277. PubMed ID: 37754515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
    Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
    Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
    Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
    J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
    Li X; Wu S; Zhang L; Zhu J; Xu B
    Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer.
    Yin Y; Yang H; Liu Z; Tan J; Zhu C; Chen M; Zhou R; Wang L; Qian J
    Cancer Manag Res; 2020; 12():13479-13487. PubMed ID: 33408520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.
    Pei X; Liu Y; Sun L; Zhang J; Fang Y; Liao X; Liu J; Zhang C; Yin T
    Clin Colorectal Cancer; 2016 Dec; 15(4):e149-e156. PubMed ID: 27155750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line systemic therapy for metastatic colorectal cancer.
    Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
    Khattak MA; Martin H; Davidson A; Phillips M
    Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
    Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
    BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.